Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

Stopped early · Phase 2

Conditions studied: Adenocarcinoma of the Esophagus

In brief

Current therapies for Adenocarcinoma of the Esophagus provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Adenocarcinoma of the Esophagus. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Adenocarcinoma of the Esophagus.

Key facts

Study ID

NCT00003487

Run by

Burzynski Research Institute

People needed

8

Starts

1996-05-30

Expected to finish

2001-04-27

Last updated by the study team

2021-05-14

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Burzynski Clinic — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.